Phillip Md Et Al Frost Purchases 100,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock in a transaction on Tuesday, September 14th. The shares were bought at an average cost of $3.46 per share, with a total value of $346,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, August 13th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The shares were bought at an average cost of $3.69 per share, with a total value of $369,000.00.

Shares of NASDAQ OPK traded up $0.01 during midday trading on Wednesday, reaching $3.49. 8,877 shares of the company were exchanged, compared to its average volume of 5,440,146. The stock has a market cap of $2.38 billion, a P/E ratio of 31.64 and a beta of 1.75. The stock’s 50-day moving average price is $3.69 and its 200-day moving average price is $3.94. The company has a quick ratio of 1.36, a current ratio of 1.80 and a debt-to-equity ratio of 0.11. OPKO Health, Inc. has a one year low of $3.02 and a one year high of $6.27.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Thursday, July 29th. The biotechnology company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.05). The business had revenue of $442.40 million for the quarter, compared to analyst estimates of $457.57 million. OPKO Health had a return on equity of 4.21% and a net margin of 3.71%. On average, equities research analysts anticipate that OPKO Health, Inc. will post 0.04 EPS for the current year.

Several research analysts have recently commented on the stock. Barrington Research lowered their target price on shares of OPKO Health from $8.00 to $6.00 and set an “outperform” rating on the stock in a report on Friday, July 30th. LADENBURG THALM/SH SH assumed coverage on shares of OPKO Health in a research note on Monday, June 21st. They issued a “buy” rating and a $7.00 price objective on the stock.

Several large investors have recently modified their holdings of OPK. Quantbot Technologies LP lifted its holdings in OPKO Health by 129.9% in the first quarter. Quantbot Technologies LP now owns 7,294 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 4,122 shares during the period. Baillie Gifford & Co. acquired a new position in OPKO Health in the first quarter valued at $31,000. Eqis Capital Management Inc. acquired a new position in OPKO Health in the second quarter valued at $41,000. Virtu Financial LLC acquired a new position in OPKO Health in the first quarter valued at $48,000. Finally, Profund Advisors LLC acquired a new position in OPKO Health in the first quarter valued at $52,000. Institutional investors own 27.56% of the company’s stock.

About OPKO Health

OPKO Health, Inc, is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment include clinical laboratory operations of BioReference, as well as point-of-care operations.

Read More: What are defining characteristics of a correction?

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.